Monoamine oxidase inhibitors and neuroprotection: A review

American Journal of Therapeutics

Volumn 19, Issue 6, 2012, Pages 436-448

  Al Nuaimi, Saleem K ^a   MacKenzie, Erin M ^a   Baker, Glen B ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

( ) deprenyl; monoamine oxidase; Monoamine oxidase inhibitors; neuroprotection; phenelzine

Indexed keywords

ADENOSINE PHOSPHATE; ALDEHYDE; AMINE OXIDASE (FLAVIN CONTAINING); CLORGYLINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LADOSTIGIL; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROTROPHIN RECEPTOR P75; PHENELZINE; PROTEIN BCL 2; PROTEIN BCL XL; RASAGILINE; REACTIVE OXYGEN METABOLITE; SELEGILINE; TRANYLCYPROMINE;

ANTIOXIDANT ACTIVITY; CALCIUM CELL LEVEL; CELL DEATH; CELL HYPOXIA; COGNITION; DEGENERATIVE DISEASE; DEPRESSION; DISEASE SEVERITY; DRUG STRUCTURE; EXCITOTOXICITY; GABAERGIC TRANSMISSION; HUMAN; LIPID PEROXIDATION; MITOCHONDRIAL MEMBRANE POTENTIAL; NERVE CELL NECROSIS; NERVE DEGENERATION; NEURAL STEM CELL; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PANIC; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SOCIAL PHOBIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; HUMANS; MENTAL DISORDERS; MONOAMINE OXIDASE INHIBITORS; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS;

EID: 84870251836     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31825b9eb5     Document Type: Review

References (169)

1. Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7:295-309.
2. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992;59:1609-1623.
3. Lamensdorf I, Eisenhofer G, Harvey-White J, et al. 3,4- Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res. 2000; 868:191-201. (Pubitemid 30347515)
4. Shin MH, Jang JH, Surh YJ. Potential roles of NF-kappaB and ERK1/2 in cytoprotection against oxidative cell death induced by tetrahydropapaveroline. Free Radic Biol Med. 2004;36:1185-1194.
5. Yang L, Omori K, Suzukawa J, et al. Calcineurinmediated BAD Ser155 dephosphorylation in ammoniainduced apoptosis of cultured rat hippocampal neurons. Neurosci Lett. 2004;357:73-75. (Pubitemid 38186673)
6. Tabakman R, Lecht S, Lazarovici P. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? Bioessays. 2004;26:80-90. (Pubitemid 38095352)
7. Johnston JP. Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol. 1968;17:1285-1297.
8. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci. 1999;22:197-217. (Pubitemid 29144886)
9. Berry MD. The potential of trace amines and their receptors for treating neurological and psychiatric diseases. Rev Recent Clin Trials. 2007;2:3-19. (Pubitemid 46723183)
10. Boulton AA, Baker GB, Dewhurst WG, et al. Neurobiology of the Trace Amines: Analytical, Physiological, Pharmacological, Behavioral, and Clinical Aspects. Clifton, NJ: Humana Press; 1984.
11. Boulton AA, Downer RGH, Juorio AV. Trace Amines: Comparative and Clinical Neurobiology. Clifton, NJ: Humana Press; 1988.
12. Mosnaim AD, Wolf ME. Noncatecholic Phenylethylamines. New York, NY: M. Dekker; 1978.
13. Tomlinson S, Baker GB. Trace amines. In: Stolerman IP, ed. Encyclopedia of Psychopharmacology. Berlin, Germany: Springer; 2010.
14. Yu PH, Tipton KF. Deuterium isotope effect of phenelzine on the inhibition of rat liver mitochondrial monoamine oxidase activity. Biochem Pharmacol. 1989; 38:4245-4251. (Pubitemid 20009023)
15. Davis DS, Tasuhara H, Boobis AR, et al. The effects of reversible inhibitors of monoamine oxidase on tyramine deamination in dog intestine. In: Tipton KF, Dostert P, Strolin-Benedetti M, eds. Monoamine Oxidase and Disease. London, United Kingdom: Academic Press; 1984.
16. Hasan F, McCrodden JM, Kennedy NP, et al. The involvement of intestinal monoamine oxidase in the transport and metabolism of tyramine. J Neural Transm Suppl. 1988;26:1-9.
17. Blackwell B. Hypertensive crisis due to monoamineoxidase inhibitors. Lancet. 1963;2:849-850.
18. Knoll J. (-)Deprenyl (Selegiline): past, present and future. Neurobiology (Bp). 2000;8:179-199.
19. Anderson MC, Hasan F, McCrodden JM, et al. Monoamine oxidase inhibitors and the cheese effect. Neurochem Res. 1993;18:1145-1149. (Pubitemid 23306348)
20. Frampton JE, Plosker GL. Selegiline transdermal system: in the treatment of major depressive disorder. Drugs. 2007;67:257-265; discussion 266-267.
21. Parkinson Study Group, A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937-1943.
22. Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med. 1989;321:1364-1371.
23. Chetsawang B, Kooncumchoo P, Govitrapong P, et al. 1-Methyl-4-phenyl- pyridinium ion-induced oxidative stress, c-Jun phosphorylation and DNA fragmentation factor-45 cleavage in SK-N-SH cells are averted by selegiline. Neurochem Int. 2008;53:283-288.
24. Ebadi M, Sharma S, Shavali S, et al. Neuroprotective actions of selegiline. J Neurosci Res. 2002;67:285-289. (Pubitemid 34137134)
25. Finnegan KT, Skratt JJ, Irwin I, et al. Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Eur J Pharmacol. 1990;184: 119-126. (Pubitemid 20261678)
26. Munirathinam S, Lakshmana MK, Raju TR. (-) deprenyl attenuates aluminium induced neurotoxicity in primary cortical cultures. Neurodegeneration. 1996;5:161-167. (Pubitemid 26248606)
27. Saravanan KS, Sindhu KM, Senthilkumar KS, et al. L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats. Neurochem Int. 2006;49:28-40.
28. Sharma SK, Carlson EC, Ebadi M. Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons. J Neurocytol. 2003;32:329-343. (Pubitemid 38197813)
29. Sowa BN, Holt A, Todd KG, et al. Monoamine oxidase inhibitors, their structural analogues, and neuroprotection. Indian J Exp Biol. 2004;42:851-857. (Pubitemid 39187841)
30. Tatton W, Chalmers-Redman R, Tatton N. Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B. J Neural Transm. 2003;110: 509-515. (Pubitemid 36543282)
31. Abu-Raya S, Tabakman R, Blaugrund E, et al. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol. 2002;434:109-116. (Pubitemid 34056569)
32. Buys YM, Trope GE, Tatton WG. (-)-Deprenyl increases the survival of rat retinal ganglion cells after optic nerve crush. Curr Eye Res. 1995;14:119-126.
33. Knollema S, Aukema W, Hom H, et al. L-deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia. Stroke. 1995;26:1883-1887.
34. Maruyama W, Takahashi T, Naoi M. (-)-Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J Neurochem. 1998;70:2510-2515. (Pubitemid 28252377)
35. Mytilineou C, Radcliffe P, Leonardi EK, et al. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem. 1997;68:33-39. (Pubitemid 26427289)
36. Salonen T, Haapalinna A, Heinonen E, et al. Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity. Acta Neuropathol. 1996;91:466-474. (Pubitemid 26133657)
37. Semkova I,Wolz P, Schilling M, et al. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur J Pharmacol. 1996;315:19-30. (Pubitemid 26390945)
38. Seniuk NA, Henderson JT, Tatton WG, et al. Increased CNTF gene expression in process-bearing astrocytes following injury is augmented by R(-)-deprenyl. J Neurosci Res. 1994;37:278-286. (Pubitemid 24054655)
39. Seymour CB, Mothersill C, Mooney R, et al. Monoamine oxidase inhibitors l-deprenyl and clorgyline protect nonmalignant human cells from ionising radiation and chemotherapy toxicity. Br J Cancer. 2003;89:1979-1986. (Pubitemid 37533280)
40. Tatton WG, Ju WY, Holland DP, et al. (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem. 1994;63:1572-1575. (Pubitemid 24299550)
41. Todd KG, Butterworth RF. Increased neuronal cell survival after L-deprenyl treatment in experimental thiamine deficiency. J Neurosci Res. 1998;52:240-246. (Pubitemid 28186168)
42. Baker GB, Sowa B, Todd KG. Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007;32:313-315. (Pubitemid 47492755)
43. Fowler CJ, Wiberg A, Oreland L, et al. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm. 1980;49: 1-20. (Pubitemid 10030548)
44. Jossan SS, Gillberg PG, Gottfries CG, et al. Monoamine oxidase B in brains from patients with Alzheimer's disease: a biochemical and autoradiographical study. Neuroscience. 1991;45:1-12.
45. Cao X, Wei Z, Gabriel GG, et al. Calcium-sensitive regulation of monoamine oxidase-A contributes to the production of peroxyradicals in hippocampal cultures: implications for Alzheimer disease-related pathology. BMC Neurosci. 2007;8:73.
46. Meyer JH, Ginovart N, Boovariwala A, et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006;63:1209-1216. (Pubitemid 44708079)
47. Meyer JH,Wilson AA, Sagrati S, et al. Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. Arch Gen Psychiatry. 2009;66:1304-1312.
48. Lewinsohn R. Amine oxidase in human blood vessels and non-vascular smooth muscle. J Pharm Pharmacol. 1981;33:569-575. (Pubitemid 11028290)
49. Lizcano JM, Fernandez de Arriba A, Tipton KF, et al. Inhibition of bovine lung semicarbazide-sensitive amine oxidase (SSAO) by some hydrazine derivatives. Biochem Pharmacol. 1996;52:187-195. (Pubitemid 26233747)
50. Zuo DM, Yu PH. Semicarbazide-sensitive amine oxidase and monoamine oxidase in rat brain microvessels, meninges, retina and eye sclera. Brain Res Bull. 1994;33: 307-311.
51. Matyus P, Dajka-Halasz B, Foldi A, et al. Semicarbazidesensitive amine oxidase: current status and perspectives. Curr Med Chem. 2004;11:1285-1298. (Pubitemid 38585067)
52. del Mar Hernandez M, Esteban M, Szabo P, et al. Human plasma semicarbazide sensitive amine oxidase (SSAO), beta-amyloid protein and aging. Neurosci Lett. 2005;384: 183-187. (Pubitemid 40826641)
53. Ferrer I, Lizcano JM, Hernandez M, et al. Overexpression of semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer's disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurosci Lett. 2002;321:21-24. (Pubitemid 34185489)
54. Wood PL, Khan MA, Moskal JR, et al. Aldehyde load in ischemia-reperfusion brain injury: neuroprotection by neutralization of reactive aldehydes with phenelzine. Brain Res. 2006;1122:184-190. (Pubitemid 44708115)
55. Seiler N. Oxidation of polyamines and brain injury. Neurochem Res. 2000;25:471-490. (Pubitemid 30317680)
56. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991;11:81-128. (Pubitemid 121003917)
57. Uchida K, Kanematsu M, Sakai K, et al. Protein-bound acrolein: potential markers for oxidative stress. Proc Natl Acad Sci USA. 1998;95:4882-4887. (Pubitemid 28208519)
58. Tomitori H, Usui T, Saeki N, et al. Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke. Stroke. 2005;36:2609-2613.
59. Lovell MA, Xie C, Markesbery WR. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging. 2001;22:187-194. (Pubitemid 32162967)
60. Picklo MJ, Montine TJ. Acrolein inhibits respiration in isolated brain mitochondria. Biochim Biophys Acta. 2001; 1535:145-152. (Pubitemid 32114142)
61. Gubisne-Haberle D, Hill W, Kazachkov M, et al. Protein cross-linkage induced by formaldehyde derived from semicarbazide-sensitive amine oxidase-mediated deamination of methylamine. J Pharmacol Exp Ther. 2004;310: 1125-1132. (Pubitemid 39108934)
62. Ivanova S, Botchkina GI, Al-Abed Y, et al. Cerebral ischemia enhances polyamine oxidation: identification of enzymatically formed 3-aminopropanal as an endogenous mediator of neuronal and glial cell death. J ExpMed. 1998; 188:327-340. (Pubitemid 28357761)
63. Li W, Yuan XM, Ivanova S, et al. 3-aminopropanal, formed during cerebral ischaemia, is a potent lysosomotropic neurotoxin. Biochem J. 2003;371(pt 2):429-436. (Pubitemid 36547626)
64. Horton ND, Mamiya BM, Kehrer JP. Relationships between cell density, glutathione and proliferation of A549 human lung adenocarcinoma cells treated with acrolein. Toxicology. 1997;122:111-122. (Pubitemid 27327031)
65. White JS, Rees KR. The mechanism of action of 4-hydroxynonenal in cell injury. Chem Biol Interact. 1984;52:233-241. (Pubitemid 15222858)
66. Calingasan NY, Uchida K, Gibson GE. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J Neurochem. 1999;72:751-756. (Pubitemid 29055239)
67. Markesbery WR, Lovell MA. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol Aging. 1998;19:33-36. (Pubitemid 28167792)
68. Sayre LM, Zelasko DA, Harris PL, et al.4-Hydroxynonenalderived advanced lipid peroxidation end products are increased in Alzheimer's disease. J Neurochem. 1997;68: 2092-2097. (Pubitemid 27176147)
69. Pocernich CB, Butterfield DA. Acrolein inhibits NADHlinked mitochondrial enzyme activity: implications for Alzheimer's disease. Neurotox Res. 2003;5:515-520.
70. Chen K, Maley J, Yu PH. Potential inplications of endogenous aldehydes in beta-amyloid misfolding, oligomerization and fibrillogenesis. J Neurochem. 2006; 99:1413-1424. (Pubitemid 44730095)
71. Nie CL, Wei Y, Chen X, et al. Formaldehyde at low concentration induces protein tau into globular amyloid-like aggregates in vitro and in vivo. PLoS One. 2007;2:e629.
72. Yu PH. Involvement of cerebrovascular semicarbazidesensitive amine oxidase in the pathogenesis of Alzheimer's disease and vascular dementia. Med Hypotheses. 2001;57:175-179. (Pubitemid 32681640)
73. Burcham PC, Kaminskas LM, Fontaine FR, et al. Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products. Toxicology. 2002; 181-182:229-236.
74. Galvani S, Coatrieux C, Elbaz M, et al. Carbonyl scavenger and antiatherogenic effects of hydrazine derivatives. Free Radic Biol Med. 2008;45:1457-1467.
75. Song MS, Baker GB, Dursun SM, et al. The antidepressant phenelzine protects neurons and astrocytes against formaldehyde-induced toxicity. J Neurochem. 2010;114: 1405-1413.
76. Baker GB, Wong JT, Yeung JM, et al. Effects of the antidepressant phenelzine on brain levels of gammaaminobutyric acid (GABA). J Affect Disord. 1991;21: 207-211.
77. Popov N,Matthies H. Some effects of monoamine oxidase inhibitors on the metabolism of gamma-aminobutyric acid in rat brain. J Neurochem. 1969;16:899-907.
78. Iqbal S, Baziany A, Gordon S, et al. Neuroprotective effect of tiagabine in transient forebrain global ischemia: an in vivo microdialysis, behavioral, and histological study. Brain Res. 2002;946:162-170. (Pubitemid 34876328)
79. Juurlink BH, Sweeney MI. Mechanisms that result in damage during and following cerebral ischemia. Neurosci Biobehav Rev. 1997;21:121-128. (Pubitemid 27102557)
80. Kanthan R, Shuaib A,Griebel R, et al. Intracerebral human microdialysis. In vivo study of an acute focal ischemic model of the human brain. Stroke. 1995;26:870-873.
81. Yang Y, Li Q, Miyashita H, et al. Different dynamic patterns of extracellular glutamate release in rat hippocampus after permanent or 30-min transient cerebral ischemia and histological correlation. Neuropathology. 2001;21:181-187. (Pubitemid 32947281)
82. Baldwin HA, Colado MI, Murray TK, et al. Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine. Br J Pharmacol. 1993;108:590-596. (Pubitemid 23067922)
83. Kang TC, Park SK, Bahn JH, et al. Elevation of the gamma-aminobutyric acid transaminase expression in the gerbil CA1 area after ischemia-reperfusion damage. Neurosci Lett. 2000;294:33-36.
84. Mainprize T, Shuaib A, Ijaz S, et al. GABA concentrations in the striatum following repetitive cerebral ischemia. Neurochem Res. 1995;20:957-961.
85. Schwartz-Bloom RD, Sah R. gamma-Aminobutyric acid(A) neurotransmission and cerebral ischemia. J Neurochem. 2001;77:353-371. (Pubitemid 32303172)
86. Shuaib A, Ijaz S, Miyashita H, et al. Progressive decrease in extracellular GABA concentrations in the postischemic period in the striatum: a microdialysis study. Brain Res. 1994;666:99-103. (Pubitemid 24359657)
87. Zeng X, Zhang Y, Zhang S, et al. A microdialysis study of effects of gastrodin on neurochemical changes in the ischemic/reperfused rat cerebral hippocampus. Biol Pharm Bull. 2007;30:801-804. (Pubitemid 46570994)
88. Green AR, Hainsworth AH, Jackson DM. GABA potentiation: a logical pharmacological approach for the treatment of acute ischaemic stroke. Neuropharmacology. 2000;39:1483-1494. (Pubitemid 30330866)
89. Shuaib A, Kanthan R. Amplification of inhibitory mechanisms in cerebral ischemia: an alternative approach to neuronal protection. Histol Histopathol. 1997;12: 185-194. (Pubitemid 27106930)
90. Michael-Titus AT, Bains S, Jeetle J, et al. Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex-a possible mechanism of neuroprotection in major depression? Neuroscience. 2000;100:681-684.
91. Cowburn R, Hardy J, Roberts P, et al. Presynaptic and postsynaptic glutamatergic function in Alzheimer's disease. Neurosci Lett. 1988;86:109-113. (Pubitemid 18064401)
92. Liang Z, Valla J, Sefidvash-Hockley S, et al. Effects of estrogen treatment on glutamate uptake in cultured human astrocytes derived from cortex of Alzheimer's disease patients. J Neurochem. 2002;80:807-814. (Pubitemid 34809233)
93. Scott HL, Tannenberg AE, Dodd PR. Variant forms of neuronal glutamate transporter sites in Alzheimer's disease cerebral cortex. J Neurochem. 1995;64:2193-2202.
94. Lanctot KL, Herrmann N, Mazzotta P, et al. GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia. Can J Psychiatry. 2004;49:439-453. (Pubitemid 39071365)
95. MacKenzie EM, Song MS, Dursun SM, et al. Phenelzine: an old drug that may hold clues to the development of new neuroprotective agents. Bull Clin Psychopharmacol. 2010;20:179-186.
96. Baker GB, MacKenzie EM, Rauw GA, et al. Unique aspects of the metabolism and pharmacology of the antidepressant/antipanic drug phenelzine. Paper presented at: Canadian Society of Pharmacology and Therapeutics 2009 Conference; May 30, 2009; Saskatoon, Saskatchewan, Canada.
97. Paslawski T, Knaus E, Iqbal N, et al. b-Phenylethylidenehydrazine, a novel inhibitor of GABA transaminase. Drug Devel Res. 2001;54:35-39. (Pubitemid 33121519)
98. Todd KG, Banigesh AI, Baker GB, et al. Phenylethylidenehydrazine, a novel GABA-T inhibitor, has neuroprotective actions in transient global ischemia. Proceedings of the Joint Meeting of the International Society of Neurochemistry and the European Society of Neurochemistry, Berlin, Germany, 1999.
99. Lauderback CM, Hackett JM, Huang FF, et al. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Abeta1-42. J Neurochem. 2001;78:413-416. (Pubitemid 32664423)
100. Kawaguchi M, Shibata N, Horiuchi S, et al. Glyoxal inactivates glutamate transporter-1 in cultured rat astrocytes. Neuropathology. 2005;25:27-36. (Pubitemid 40477710)
101. Maragakis NJ, Dietrich J, Wong V, et al. Glutamate transporter expression and function in human glial progenitors. Glia. 2004;45:133-143. (Pubitemid 38196990)
102. Maragakis NJ, Rothstein JD. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol. 2006;2:679-689. (Pubitemid 44782682)
103. Riederer P, Lachenmayer L, Laux G. Clinical applications of MAO-inhibitors. Curr Med Chem. 2004;11:2033-2043. (Pubitemid 38967728)
104. Birks J, Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev. 2003;(1):CD000442.
105. Cohen G, Pasik P, Cohen B, et al. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) inmonkeys. Eur J Pharmacol. 1984;106:209-210. (Pubitemid 15189049)
106. Langston JW, Ballard P, Tetrud JW, et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979-980. (Pubitemid 13189531)
107. Grimsby J, Toth M, Chen K, et al. Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat Genet. 1997;17:206-210.
108. Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun. 1984;120:574-578. (Pubitemid 14101750)
109. Magyar K. Behaviour of (-)-deprenyl and its analogues. J Neural Transm Suppl. 1994;41:167-175. (Pubitemid 24215689)
110. Berry MD, Boulton AA. Aliphatic propargylamines as symptomatic and neuroprotective treatments for neurodegenerative diseases. Neurotoxicol Teratol. 2002;24: 667-673. (Pubitemid 35013526)
111. Yu PH, Davis BA, Boulton AA. Aliphatic propargylamines, a new series of potent selective, irreversible nonamphetamine-like MAO-B inhibitors. Their structures, function and pharmacological implications. Adv Exp Med Biol. 1995;363:17-23.
112. Naoi M, MaruyamaW, Takahashi T, et al. Involvement of endogenous N-methyl(R)salsolinol in Parkinson's disease: induction of apoptosis and protection by (-)deprenyl. J Neural Transm Suppl. 2000;58:111-121.
113. de la Cruz CP, Revilla E, Steffen V, et al. Protection of the aged substantia nigra of the rat against oxidative damage by (-)-deprenyl. Br J Pharmacol. 1996;117:1756-1760. (Pubitemid 26121622)
114. Tatton WG, Chalmers-Redman RM, Ju WJ, et al. Propargylamines induce antiapoptotic new protein synthesis in serum-and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther. 2002;301:753-764. (Pubitemid 34429993)
115. Tatton WG, Greenwood CE. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res. 1991;30:666-672.
116. Fernandez HH, Chen JJ. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin Neuropharmacol. 2007;30:150-168. (Pubitemid 46871865)
117. Stocchi F, Olanow CW. Neuroprotection in Parkinson's disease: clinical trials. Ann Neurol. 2003;53(suppl 3): S87-S97; discussion S97-S99.
118. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39:889-909. (Pubitemid 37130207)
119. Carrillo MC, Kanai S, Nokubo M, et al. (-) Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci. 1991;48:517-521.
120. Carrillo MC, Kanai S, Sato Y, et al. The optimal dosage of (-)deprenyl for increasing superoxide dismutase activities in several brain regions decreases with age in male Fischer 344 rats. Life Sci. 1993;52:1925-1934.
121. Xiao H, Lv F, Xu W, et al. Deprenyl prevents MPP(+)-induced oxidative damage in PC12 cells by the upregulation of Nrf2-mediated NQO1 expression through the activation of PI3K/Akt and Erk. Toxicology. 2011;290:286-294.
122. 122.Maruyama W, Weinstock M, Youdim MB, et al. Antiapoptotic action of anti-Alzheimer drug, TV3326 [(Npropargyl)-( 3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine oxidase inhibitor. Neurosci Lett. 2003;341:233-236. (Pubitemid 36403771)
123. Gassen M, Lamensdorf I, Armony T, et al. Attenuation of methamphetamine induced dopaminergic neurotoxicity by flupirtine: microdialysis study on dopamine release and free radical generation. J Neural Transm. 2003;110: 171-182. (Pubitemid 36216499)
124. Finberg JP, Lamensdorf I, Weinstock M, et al. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol. 1999;80:495-499.
125. Akao Y, Maruyama W, Shimizu S, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)- aminoindan. J Neurochem. 2002;82:913-923.
126. Abu-Raya S, Blaugrund E, Trembovler V, et al. Rasagiline, a monoamine oxidase-B inhibitor, protects NGFdifferentiated PC12 cells against oxygen-glucose deprivation. J Neurosci Res. 1999;58:456-463. (Pubitemid 29508580)
127. Weinreb O, Bar-Am O, Amit T, et al. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 2004;18:1471-1473. (Pubitemid 39561618)
128. Akao Y, Maruyama W, Yi H, et al. An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett. 2002;326: 105-108. (Pubitemid 34607570)
129. Maruyama W, Akao Y, Carrillo MC, et al. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 2002;24:675-682. (Pubitemid 35013527)
130. Maruyama W, Akao Y, Youdim MB, et al. Transfectionenforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl( R)salsolinol. J Neurochem. 2001;78:727-735. (Pubitemid 32777974)
131. 131.Maruyama W, Youdim MB, Naoi M. Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann N Y Acad Sci. 2001;939:320-329. (Pubitemid 32620083)
132. Maruyama W, Takahashi T, Youdim M, et al. The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm. 2002; 109:467-481. (Pubitemid 34280405)
133. Ou XM, Lu D, Johnson C, et al. Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009;16:148-159.
134. Ou XM, Stockmeier CA, Meltzer HY, et al. A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage. Biol Psychiatry. 2010;67:855-863.
135. Yogev-Falach M, Amit T, Bar-Am O, et al. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing. FASEB J. 2003;17:2325-2327. (Pubitemid 39561481)
136. Bar-Am O, Amit T, Youdim MB. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem. 2007;103:500-508. (Pubitemid 47498024)
137. Speiser Z, Levy R, Cohen S. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl. 1998;52:287-300.
138. Bar-Am O,Weinreb O, Amit T, et al. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neurochem. 2010; 112:1131-1137.
139. Tazik S, Johnson S, Lu D, et al. Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotox Res. 2009;15:284-290.
140. Speiser Z, Mayk A, Eliash S, et al. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm. 1999;106:593-606. (Pubitemid 29401349)
141. Speiser Z, Mayk A, Litinetsky L, et al. Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat. J Neural Transm. 2007;114:595-605. (Pubitemid 46664052)
142. Speiser Z, Katzir O, Rehavi M, et al. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol Biochem Behav. 1998;60: 387-393. (Pubitemid 28282679)
143. Eliash S, Shteter N, Eilam R. Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model. J Neural Transm. 2005;112:991-1003. (Pubitemid 40991515)
144. Eliash S, Speiser Z, Cohen S. Rasagiline and its (S) enantiomer increase survival and prevent stroke in saltloaded stroke-prone spontaneously hypertensive rats. J Neural Transm. 2001;108:909-923. (Pubitemid 32802090)
145. Huang W, Chen Y, Shohami E, et al. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol. 1999;366:127-135. (Pubitemid 29080775)
146. Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol. 2008;210:421-427.
147. Eliash S, Dror V, Cohen S, et al. Neuroprotection by rasagiline in thiamine deficient rats. Brain Res. 2009;1256: 138-148.
148. Bar-Am O, Weinreb O, Amit T, et al. The novel cholinesterase-monoamine oxidase inhibitor and antioxidant, ladostigil, confers neuroprotection in neuroblastoma cells and aged rats. J Mol Neurosci. 2009;37: 135-145.
149. Weinreb O, Bar-Am O, Amit T, et al. The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity. Chem Biol Interact. 2008;175:318-326.
150. Weinstock M, Kirschbaum-Slager N, Lazarovici P, et al. Neuroprotective effects of novel cholinesterase inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann N Y Acad Sci. 2001;939:148-161. (Pubitemid 32620064)
151. Yogev-Falach M, Bar-Am O, Amit T, et al. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing. FASEB J. 2006; 20:2177-2179.
152. Chiou SH, Ku HH, Tsai TH, et al. Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway. Br J Pharmacol. 2006; 148:587-598.
153. Malorni W, Giammarioli AM, Matarrese P, et al. Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett. 1998;426:155-159. (Pubitemid 28198175)
154. Maragos WF, Young KL, Altman CS, et al. Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgyline-treated rats and MAO-A deficient mice. Neurochem Res. 2004;29: 741-746. (Pubitemid 38429192)
155. Gillman PK. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol. 2011;31:66-74.
156. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995;15:7539-7547.
157. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci. 1996;16:2365-2372. (Pubitemid 26154346)
158. Santarelli L, Saxe M, Gross C, et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science. 2003;301:805-809. (Pubitemid 36962615)
159. Yi H, Maruyama W, Akao Y, et al. N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm. 2006;113:21-32. (Pubitemid 41828953)
160. Maruyama W, Nitta A, Shamoto-Nagai M, et al. NPropargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NFkappaB transcription factor. Neurochem Int. 2004;44: 393-400. (Pubitemid 37548404)
161. Susin SA, Lorenzo HK, Zamzami N, et al. Mitochondrial release of caspase-2 and-9 during the apoptotic process. J Exp Med. 1999;189:381-394.
162. Tatton WG, Wadia JS, Ju WY, et al. (-)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase. J Neural Transm Suppl. 1996;48:45-59. (Pubitemid 26423346)
163. Segal RA. Selectivity in neurotrophin signaling: theme and variations. Annu Rev Neurosci. 2003;26:299-330. (Pubitemid 37064936)
164. Balu DT, Hoshaw BA, Malberg JE, et al. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res. 2008;1211:37-43.
165. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59: 1116-1127.
166. Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression. Neuron. 2002;34:13-25. (Pubitemid 34270695)
167. Mizuta I, Ohta M, Ohta K, et al. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun. 2000;279:751-755. (Pubitemid 32042852)
168. Li XM, Qi J, Juorio AV, et al. Reduction in glial fibrillary acidic protein mRNA abundance induced by (-)-deprenyl and other monoamine oxidase B inhibitors in C6 glioma cells. J Neurochem. 1993;61:1573-1576. (Pubitemid 23285125)
169. Gyarfas T, Knuuttila J, Lindholm P, et al. Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-parkinsonian drug therapy in vivo. Cell Mol Neurobiol. 2010;30: 361-368.